CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today announced the pricing of its underwritten public offering of 3,739,130 units at the public offering price of $5.75 per unit. Each unit consists of one share of common stock and six-tenths (0.6) of a warrant to purchase one share of common stock with an exercise price of $6.60 per share. All units in the offering are to be sold by BIND. The gross proceeds to BIND from this offering are expected to be approximately $21.5 million, not including any future proceeds from the exercise of the warrants.
Cowen and Company and Stifel are acting as joint book-running managers for the offering. JMP Securities is acting as lead manager and Oppenheimer & Co. is acting as co-manager for the offering.
Help employers find you! Check out all the jobs and post your resume.
